EP Patent

EP2331537B1 — 1-((5-heteroarylthiazol-2-yl)aminocarbonyl)pyrrolidine-2-carboxamide derivatives as phosphatidylinositol 3-kinase (pi3k) inhibitors useful in the treatment of proliferative diseases

Assigned to Novartis AG · Expires 2015-10-28 · 11y expired

What this patent protects

Patent listed against Piqray.

Drugs covered by this patent

Patent Metadata

Patent number
EP2331537B1
Jurisdiction
EP
Classification
—
Expires
2015-10-28
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.